Our team

Who is behind our education content

How we prepare, source and check our peptide education, under a research-use-only framework.

Researchers whose work we cite

Our education articles summarize published studies. These are researchers who wrote papers we draw on, shown with the paper and the affiliation printed on it.

These researchers are not our employees, advisors or reviewers, and they have not endorsed US Peptide Science or any product we sell. They are listed only because we cite their published work.

Albert Dahan

Cited researcher

Department of Anesthesiology, Leiden University Medical Center, Leiden, the Netherlands (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Targeting the innate repair receptor to treat neuropathy · Pain Rep, 2016 · First author · DOI 10.1097/PR9.0000000000000566

Google Scholar PubMed

Michael Brines

Cited researcher

Araim Pharmaceuticals, Tarrytown, NY, USA (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Targeting the innate repair receptor to treat neuropathy · Pain Rep, 2016 · Co-author · DOI 10.1097/PR9.0000000000000566

Google Scholar PubMed

Hazel H. Szeto

Cited researcher

Research Program in Mitochondrial Therapeutics, Department of Pharmacology, Weill Medical College of Cornell University, New York, NY, USA (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics · Br J Pharmacol, 2014 · First author · DOI 10.1111/bph.12461

Google Scholar PubMed

Loren Pickart

Cited researcher

Skin Biology Research & Development, Bellevue, WA, USA (as listed on the paper)

Author of 2 papers summarized in our education library, cited in 2 of our articles.

Selected publications

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · Biomed Res Int, 2015 · First author · DOI 10.1155/2015/648108
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · Int J Mol Sci, 2018 · First author · DOI 10.3390/ijms19071987

Google Scholar PubMed

Anna Margolina

Cited researcher

Skin Biology Research & Development, Bellevue, WA, USA (as listed on the paper)

Author of 2 papers summarized in our education library, cited in 2 of our articles.

Selected publications

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · Biomed Res Int, 2015 · Senior (last) author · DOI 10.1155/2015/648108
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · Int J Mol Sci, 2018 · Senior (last) author · DOI 10.3390/ijms19071987

Google Scholar PubMed

V. Kh. Khavinson

Cited researcher

St. Petersburg Institute of Bioregulation and Gerontology, Russian Academy of Medical Sciences (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells · Bull Exp Biol Med, 2003 · First author · DOI 10.1023/a:1025493705728

Google Scholar PubMed

K. Raun

Cited researcher

Department of GH Biology, Novo Nordisk A/S, Måløv, Denmark (at time of publication) (as listed on the paper)

Author of a paper summarized in our education library, cited in 2 of our articles.

Selected publications

Ipamorelin, the first selective growth hormone secretagogue · Eur J Endocrinol, 1998 · First author · DOI 10.1530/eje.0.1390552

Google Scholar PubMed

Lawrence A. Frohman

Cited researcher

Author of a paper summarized in our education library, cited in 2 of our articles.

Selected publications

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · J Clin Endocrinol Metab, 2006 · Senior (last) author · DOI 10.1210/jc.2005-1536

Google Scholar PubMed

T. D. Müller

Cited researcher

Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, Neuherberg, Germany (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Glucagon-like peptide 1 (GLP-1) · Mol Metab, 2019 · First author · DOI 10.1016/j.molmet.2019.09.010

Google Scholar PubMed

M. H. Tschöp

Cited researcher

German Center for Diabetes Research (DZD), Neuherberg, Germany (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Glucagon-like peptide 1 (GLP-1) · Mol Metab, 2019 · Senior (last) author · DOI 10.1016/j.molmet.2019.09.010

Google Scholar PubMed

Ania M. Jastreboff

Cited researcher

Yale University School of Medicine, New Haven, CT, USA (as listed on the paper)

Author of a paper summarized in our education library, cited in 2 of our articles.

Selected publications

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · New England Journal of Medicine, 2023 · First author · DOI 10.1056/NEJMoa2301972

Google Scholar PubMed ORCID

Arun J. Sanyal

Cited researcher

Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, VA, USA (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial · Nature Medicine, 2024 · First author · DOI 10.1038/s41591-024-03018-2

Google Scholar PubMed ORCID

Lee M. Kaplan

Cited researcher

Section of Obesity Medicine and Weight and Wellness Center, Geisel School of Medicine at Dartmouth, Hanover, NH, USA (as listed on the paper)

Author of 2 papers summarized in our education library, cited in 3 of our articles.

Selected publications

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · New England Journal of Medicine, 2023 · Co-author · DOI 10.1056/NEJMoa2301972
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial · Nature Medicine, 2024 · Co-author · DOI 10.1038/s41591-024-03018-2

Google Scholar PubMed

Mark L. Hartman

Cited researcher

Eli Lilly and Company, Indianapolis, IN, USA (as listed on the paper)

Author of 2 papers summarized in our education library, cited in 3 of our articles.

Selected publications

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · New England Journal of Medicine, 2023 · Senior (last) author · DOI 10.1056/NEJMoa2301972
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial · Nature Medicine, 2024 · Senior (last) author · DOI 10.1038/s41591-024-03018-2

Google Scholar PubMed ORCID

Ming-Wei Wang

Cited researcher

Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, China (as listed on the paper)

Author of a paper summarized in our education library, cited in 4 of our articles.

Selected publications

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide · Cell Discovery, 2024 · Senior (last) author · DOI 10.1038/s41421-024-00700-0

Google Scholar PubMed ORCID

Henrique Veiga-Fernandes

Cited researcher

Champalimaud Research, Champalimaud Foundation, Lisbon, Portugal (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Neuroepithelial VIP–VIPR1 interactions differentially control enteric type 1 and type 2 immunity · Nature Immunology, 2025 · Senior (last) author · DOI 10.1038/s41590-025-02326-0

Google Scholar PubMed ORCID

Daniel M. Cushman

Cited researcher

Department of Physical Medicine & Rehabilitation, University of Utah, Salt Lake City, UT, USA (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · Curr Rev Musculoskelet Med, 2025 · Senior (last) author · DOI 10.1007/s12178-025-09990-7

Google Scholar PubMed

How our articles are made

Our articles are prepared by the US Peptide Science editorial team. They summarize published research; they are not original research and not medical advice.

1. Start from a published source

Each article is built from a specific published paper, usually from PubMed Central or a journal site. That paper is named at the bottom of the article.

2. Draft with AI assistance

Our editorial team drafts articles with the help of AI tools, asking them to summarize only what the source paper reports.

3. Check against our content rules

Every draft is checked before publishing: no disease or treatment claims, no dosing or human-use instructions, and research-use-only framing throughout.

4. Correct what we get wrong

If you spot an error or a misattributed source, tell us through the contact page and we will review and correct it.

Content standards

Researchers named on an article are the authors of the cited paper, taken from its public record at PubMed or Crossref. They are not our staff and have not endorsed us.
We describe what a study found in its own model. We do not say a compound treats, cures or prevents any condition.
We do not publish dosing, administration or human-use guidance.
All products are for in vitro laboratory research only, not for human or veterinary use.

See how we test products on the compliance page, or contact us.

Researchers whose work we cite

Our education articles summarize published studies. These are researchers who wrote papers we draw on, shown with the paper and the affiliation printed on it.

These researchers are not our employees, advisors or reviewers, and they have not endorsed US Peptide Science or any product we sell. They are listed only because we cite their published work.

Albert Dahan

Cited researcher

Department of Anesthesiology, Leiden University Medical Center, Leiden, the Netherlands (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Targeting the innate repair receptor to treat neuropathy · Pain Rep, 2016 · First author · DOI 10.1097/PR9.0000000000000566

Google Scholar PubMed

Michael Brines

Cited researcher

Araim Pharmaceuticals, Tarrytown, NY, USA (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Targeting the innate repair receptor to treat neuropathy · Pain Rep, 2016 · Co-author · DOI 10.1097/PR9.0000000000000566

Google Scholar PubMed

Hazel H. Szeto

Cited researcher

Research Program in Mitochondrial Therapeutics, Department of Pharmacology, Weill Medical College of Cornell University, New York, NY, USA (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics · Br J Pharmacol, 2014 · First author · DOI 10.1111/bph.12461

Google Scholar PubMed

Loren Pickart

Cited researcher

Skin Biology Research & Development, Bellevue, WA, USA (as listed on the paper)

Author of 2 papers summarized in our education library, cited in 2 of our articles.

Selected publications

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · Biomed Res Int, 2015 · First author · DOI 10.1155/2015/648108
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · Int J Mol Sci, 2018 · First author · DOI 10.3390/ijms19071987

Google Scholar PubMed

Anna Margolina

Cited researcher

Skin Biology Research & Development, Bellevue, WA, USA (as listed on the paper)

Author of 2 papers summarized in our education library, cited in 2 of our articles.

Selected publications

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · Biomed Res Int, 2015 · Senior (last) author · DOI 10.1155/2015/648108
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · Int J Mol Sci, 2018 · Senior (last) author · DOI 10.3390/ijms19071987

Google Scholar PubMed

V. Kh. Khavinson

Cited researcher

St. Petersburg Institute of Bioregulation and Gerontology, Russian Academy of Medical Sciences (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells · Bull Exp Biol Med, 2003 · First author · DOI 10.1023/a:1025493705728

Google Scholar PubMed

K. Raun

Cited researcher

Department of GH Biology, Novo Nordisk A/S, Måløv, Denmark (at time of publication) (as listed on the paper)

Author of a paper summarized in our education library, cited in 2 of our articles.

Selected publications

Ipamorelin, the first selective growth hormone secretagogue · Eur J Endocrinol, 1998 · First author · DOI 10.1530/eje.0.1390552

Google Scholar PubMed

Lawrence A. Frohman

Cited researcher

Author of a paper summarized in our education library, cited in 2 of our articles.

Selected publications

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · J Clin Endocrinol Metab, 2006 · Senior (last) author · DOI 10.1210/jc.2005-1536

Google Scholar PubMed

T. D. Müller

Cited researcher

Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, Neuherberg, Germany (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Glucagon-like peptide 1 (GLP-1) · Mol Metab, 2019 · First author · DOI 10.1016/j.molmet.2019.09.010

Google Scholar PubMed

M. H. Tschöp

Cited researcher

German Center for Diabetes Research (DZD), Neuherberg, Germany (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Glucagon-like peptide 1 (GLP-1) · Mol Metab, 2019 · Senior (last) author · DOI 10.1016/j.molmet.2019.09.010

Google Scholar PubMed

Ania M. Jastreboff

Cited researcher

Yale University School of Medicine, New Haven, CT, USA (as listed on the paper)

Author of a paper summarized in our education library, cited in 2 of our articles.

Selected publications

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · New England Journal of Medicine, 2023 · First author · DOI 10.1056/NEJMoa2301972

Google Scholar PubMed ORCID

Arun J. Sanyal

Cited researcher

Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, VA, USA (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial · Nature Medicine, 2024 · First author · DOI 10.1038/s41591-024-03018-2

Google Scholar PubMed ORCID

Lee M. Kaplan

Cited researcher

Section of Obesity Medicine and Weight and Wellness Center, Geisel School of Medicine at Dartmouth, Hanover, NH, USA (as listed on the paper)

Author of 2 papers summarized in our education library, cited in 3 of our articles.

Selected publications

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · New England Journal of Medicine, 2023 · Co-author · DOI 10.1056/NEJMoa2301972
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial · Nature Medicine, 2024 · Co-author · DOI 10.1038/s41591-024-03018-2

Google Scholar PubMed

Mark L. Hartman

Cited researcher

Eli Lilly and Company, Indianapolis, IN, USA (as listed on the paper)

Author of 2 papers summarized in our education library, cited in 3 of our articles.

Selected publications

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · New England Journal of Medicine, 2023 · Senior (last) author · DOI 10.1056/NEJMoa2301972
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial · Nature Medicine, 2024 · Senior (last) author · DOI 10.1038/s41591-024-03018-2

Google Scholar PubMed ORCID

Ming-Wei Wang

Cited researcher

Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, China (as listed on the paper)

Author of a paper summarized in our education library, cited in 4 of our articles.

Selected publications

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide · Cell Discovery, 2024 · Senior (last) author · DOI 10.1038/s41421-024-00700-0

Google Scholar PubMed ORCID

Henrique Veiga-Fernandes

Cited researcher

Champalimaud Research, Champalimaud Foundation, Lisbon, Portugal (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Neuroepithelial VIP–VIPR1 interactions differentially control enteric type 1 and type 2 immunity · Nature Immunology, 2025 · Senior (last) author · DOI 10.1038/s41590-025-02326-0

Google Scholar PubMed ORCID

Daniel M. Cushman

Cited researcher

Department of Physical Medicine & Rehabilitation, University of Utah, Salt Lake City, UT, USA (as listed on the paper)

Author of a paper summarized in our education library.

Selected publications

Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · Curr Rev Musculoskelet Med, 2025 · Senior (last) author · DOI 10.1007/s12178-025-09990-7

Google Scholar PubMed

How our articles are made

Our articles are prepared by the US Peptide Science editorial team. They summarize published research; they are not original research and not medical advice.

1. Start from a published source

Each article is built from a specific published paper, usually from PubMed Central or a journal site. That paper is named at the bottom of the article.

2. Draft with AI assistance

Our editorial team drafts articles with the help of AI tools, asking them to summarize only what the source paper reports.

3. Check against our content rules

Every draft is checked before publishing: no disease or treatment claims, no dosing or human-use instructions, and research-use-only framing throughout.

4. Correct what we get wrong

If you spot an error or a misattributed source, tell us through the contact page and we will review and correct it.

Content standards

Researchers named on an article are the authors of the cited paper, taken from its public record at PubMed or Crossref. They are not our staff and have not endorsed us.

We describe what a study found in its own model. We do not say a compound treats, cures or prevents any condition.

We do not publish dosing, administration or human-use guidance.

All products are for in vitro laboratory research only, not for human or veterinary use.

See how we test products on the compliance page, or contact us.